Mar 12, 2020 19:00:00

Vaccines that raise resistance to all influenza are in the final stages of clinical trials

The influenza vaccine FLU-v , which promotes an immune response to all influenza strains by promoting changes in the antibody response and the immune system, has entered the final phase of clinical trials.

Immunogenicity, Safety, and Efficacy of FLU-v in Healthy Adults | Annals of Internal Medicine | American College of Physicians

https://annals.org/aim/article-abstract/2762723/immunogenicity-safety-efficacy-standalone-universal-influenza-vaccine-flu-v-healthy

Is a 'universal' flu vaccine on the horizon?
https://medicalxpress.com/news/2020-03-universal-flu-vaccine-horizon.html

A Potential Universal Flu Vaccine Just Passed an Important Clinical Trial
https://www.sciencealert.com/a-potential-universal-flu-vaccine-just-passed-its-fourth-clinical-trial

There are several influenza viruses, and the virus that spreads each year varies. Researchers predict virus strains that will spread in the future and develop vaccines based on those predictions. Currently, the effectiveness of the vaccine is low.

Research has been underway for more than 10 years to overcome this situation, and a vaccine `` Flu '' that detects specific protein regions of influenza virus and activates `` T cells '' that play a role as the control tower of the immune response -v '. A paper published on March 10, 2020 showed that Flu-v accelerated antibody responses and changes in the immune system of recipients in a randomized, double-blind, placebo-controlled trial involving 175 subjects. Reported increased immunity to the influenza virus.

Attention has been drawn to T cell-based influenza vaccines from

research results that showed that those who escaped from infection during the 2009 H1N1 influenza epidemic had immune responses to the H1N1 virus. I was The “Flu-v” development team has identified a “protein region that is likely to induce a strong immune response” among influenza viruses using a computer algorithm. Based on these results, we formulated vaccines that detect each of the four regions in the influenza virus, and designed to respond to the remaining three even if one site was mutated.

'Flu-v' has passed the clinical trials from Phase I to Phase II , and the development team is waiting for funding for Phase III . The development team described the results as 'very promising.'